Cardiorenal syndrome at different stages of chronic kidney disease

International Journal of Artificial Organs

Volumn 30, Issue 7, 2007, Pages 564-576

  Tsagalis, George ^a,b   Zerefos, S ^a   Zerefos, N ^a  

^a Ygia Hospital   (Greece)

^b NONE   (Greece)

Author keywords

Anemia; Chronic kidney disease; Dialysis; Heart failure; Hypertension; Inflammation

Indexed keywords

BLOOD PRESSURE; DIAGNOSIS; DISEASES; HEART; NITRIC OXIDE; PATHOLOGY;

ANEMIA; BASIC PARAMETERS; CARDIAC OUTPUT; CHRONIC KIDNEY DISEASE; DIFFERENT STAGES; EXTRACELLULAR VOLUMES; HEART FAILURE; HYPERTENSION; OUTPUT REGULATION; RENIN-ANGIOTENSIN SYSTEM;

CARDIOLOGY;

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CLOPIDOGREL; CONIVAPTAN; CYSTEINE; DIURETIC AGENT; FIBRINOGEN; HEMOGLOBIN; LIPOPROTEIN; NESIRITIDE; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE; THIAZIDE DIURETIC AGENT; TOLVAPTAN; VASOPRESSIN RECEPTOR ANTAGONIST;

ADRENERGIC SYSTEM; ANEMIA; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; BONE METABOLISM; CARDIORENAL SYNDROME; CHRONIC KIDNEY DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; CRITICALLY ILL PATIENT; DIALYSIS; HEART FAILURE; HEART OUTPUT; HEMODYNAMICS; HUMAN; HYPERTENSION; INFLAMMATION; INSULIN SENSITIVITY; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; METABOLIC ACIDOSIS; METABOLIC DISORDER; MINERAL METABOLISM; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PREVALENCE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; SODIUM RESTRICTION; ULTRAFILTRATION;

EID: 34748925028     PISSN: 03913988     EISSN: None     Source Type: Journal    
DOI: 10.1177/039139880703000703     Document Type: Review

References (88)

1. Lindner A, Charra B, Sherrard DJ, Scribner BH. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 1974; 290: 697-701.
2. Ritz E. Minor renal dysfunction: an emerging independent cardiovascular risk factor. Heart 2003; 89: 963-4.
3. Guyton AC. The surprising kidney-fluid mechanism for pressure control: its infinite gain! Hypertension 1990; 16: 725-30.
4. Bongartz L, Cramer JM, Doevendans PA, Joles JA, Braam B. The severe cardiorenal syndrome: "Guyton revisited". Eur Heart J 2004; 26: 11-7.
5. US Renal Data System. USRDS 1997 annual data report. Bethesda MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases 1997. Available from: http://www.usrds.org/ adr-1997.htm.
6. Cheung AK, Sarnak MJ, Yan G, Dwyer JT, Heyka RJ, Rocco. MV, Teehan BP, Levey AS. Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int 2000; 58: 353-62.
7. Foley RN, Parfrey PS, Harnett JD, Kent GM, Martin CJ, Murray DC, Barre PE. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 1995; 47: 186-92.
8. Warram JH, Gearin G, Laffel L, Krowlewski AS. Effect of duration of type 1 diabetes on the prevalence of stages of diabetic nephropathy defined by urinary albumin/creatinine ratio. J Am Soc Nephrol 1996; 7: 930-7.
9. American Diabetes Association. Clinical practice recommendations 2001. Diabetes Care 2001; 24 (suppl 1): S1-133.
10. Keane WF, Ewknoyan G. Proteinuria, albuminuria, risk assessment, detection, elimination (PARADE): a position paper of the National Kidney Foundation. Am J Kidney Dis 1999; 33: 1004-10.
11. Forman DE, Butler J, Wang Y, Abraham WT, O'Connor CM, Gottlieb SS, Loh E, Massie BM, Rich MW, Stevenson LW, Young JB, Krumholz HM. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol 2004; 43: 61-7.
12. Gottlieb SS, Abraham WT, Butler J, Forman DE, Loh E, Massie BM, O'Connor CM, Rich MW, Stevenson LW, Young JB, Krumholz HM. The prognostic importance of different definitions of worsening renal function in congestive heart failure. J Card Fail 2002; 8: 136-41.
13. US Renal Data System. USRDS 2004 annual data report: atlas of end-stage renal disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases 2004.
14. Knight EL, Glynn RJ, McIntyre KM, Mogun H, Avorn J. Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD). Am Heart J 1999; 138 (5 Pt 1): 801-3.
15. Tyroler HA. Nutrition and coronary heart disease epidemiology. Adv Exp Med Biol 1995; 369: 7-19.
16. Hampton JR, Van Veldhuisen DJ, Kleber FX, Cowley AJ, Ardia A, Block P, Cortina A, Cserhalmi L, Follath F, Jensen G, Kayanakis J, Lie KI, Mancia G, Skene AM. Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure. Second Prospective Randomized Study of Ibopamine on Mortality and Efficacy (PRIME II) Investigators. Lancet 1997; 349: 971-7.
17. Bricker NS, Fine LG, Kaplan M, Epstein M, Bourgoignie JJ, Light A. "Magnification phenomenon" in chronic renal disease. N Engl J Med 1978; 299: 1287-93.
18. Weidmann P. Pathogenesis of hypertension associated with chronic renal failure. Contrib Nephrol 1984; 41: 47-65.
19. Safar ME, London GM, Weiss YA, Milliez PL. Overhydration and rennin in hypertensive patients with terminal renal failure: a hemodynamic study. Clin Nephrol 1975; 4: 183-8.
20. Silverberg DS, Wexler D, Blum M, Keren G, Sheps D, Leibovitch E, Brosh D, Laniado S, Schwartz D, Yachnin T, Shapira I, Gavish D, Baruch R, Koifman B, Kaplan C, Steinbruch S, Iaina A. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol 2000; 35: 1737-44.
21. Silverberg DS, Wexler D, Blum M, Iaina A. The cardiorenal anemia syndrome: correcting anemia in patients with resistant congestive heart failure can improve both cardiac and renal functions and reduce hospitalizations. Clin Nephrol 2003; (suppl 1): S93-102.
22. Silverberg DS, Wexler D, Sheps D, Blum M, Keren G, Baruch R, Schwartz D, Yachnin T, Steinbruch S, Shapira I, Laniado S, Iaina A. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol 2001; 37: 1775-80.
23. Jelkmann W. Molecular biology of erythropoietin. Intern Med 2004; 43: 649-59.
24. La Ferla K, Remann C, Jelkmann W, Hellwig-Burgel T. Inhibition of erythropoietin gene expression signaling involves the transcription factors GATA-2 and NF-κB. FASEB J 2002; 16: 1811-3.
25. Westenbrink BD, Wisser FW, Voors AA, Smilde TD, Lipsic FW, Novis G, Hillege HL, Van Gilst WH, Van V, Celdhusen DJ. Anemia in CHF is not only related to impaired renal perfusion and blunted EPO production, but to fluid retention as well. Eur Heart J 2006 (Epub ahead of print).
26. Nanas JN, Matsouka C, Karageorgopoulos D, Leonti A, Tsolakis E, Drakos SG, Tsagalou EP, Maroulidis GD, Alexopoulos GP, Kanakakis JE, Anastasiou-Nana MI. Etiology of anemia in patients with advanced heart failure. J Am Coll Cardiol 2006; 48: 2485-9.
27. Archbold RA, Balami D, Al-Hajiri A, Suliman A, Liew R, Cooper J, Ranjadayalan K, Knight CJ, Deaner A, Timmis AD. Hemoglobin concentration is an independent determinant of heart failure in acute coronary syndromes: cohort analysis of 2310 patients. Am Heart J 2006; 152: 1091-5.
28. Bostrom K, Watson KE, Horn S, Wortham C, Herman IM, Demer LL. Bone morphogenetic protein expression in human atherosclerotic lesions. J Clin Invest 1993; 91: 1800-9.
29. Gouva C, Nikolopoulos P, Ioannidis JP, Siamopoulos KC. Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial. Kidney Int 2004; 66: 753-60.
30. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994; 74: 1141-8.
31. Hornig B, Landmesser U, Kohler C, Ahlersmann D, Spiekermann S, Christoph A, Tatge H, Drexler H. Comparative effect of ACE inhibition and angiotensin II type 1 receptor antagonism on bioavailability of nitric oxide in patients with coronary artery disease: role of superoxide dismutase. Circulation 2001; 103: 799-805.
32. Converse RL, Jacobsen TN, Toto RD, Jost CMT, Cosentino. F, Fouad-Tarazi F, Victor RG. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 1992; 327: 1912-8.
33. Ligtenberg G, Blankestijn PJ, Oey PL, Klein IH, Dijkhorst-Oei LT, Boomsma F, Wieneke GH, van Huffelen AC, Koomans HA. Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. N Engl J Med 1999; 340: 1321-8.
34. Jackson G, Gibbs CR, Davies MK, Lip GY. ABC of heart failure pathophysiology. Br Med J 2000; 320: 167-70.
35. Ruffolo RR Jr, Feuerstein GZ. Pharmacology of carvedilol: rationale for use in hypertension, coronary artery disease and congestive heart failure. Cardiovasc Drugs Ther 1997; 11 (suppl 1): S247-56.
36. Erami C, Zhang H, Ho JG, French DM, Faber JE. Alpha(1)-adrenoreceptor stimulation directly induces growth of vascular wall in vivo. Am J Physiol Heart Circ Physiol 2002; 283: H1577-87.
37. Liao J, Keiser JA, Scales WE, Kunkel SL, Kluger MJ. Role of epinephrine in TNF and IL-6 production from isolated perfused rat liver. Am J Physiol 1995; 268: R896-901.
38. Oddis CV, Simmons RL, Hattler BG, Finkel MS. cAMP enhances inducible nitric oxide synthase mRNA stability in cardiac myocytes. Am J Physiol 1995; 269 (Pt 2): H2044-50.
39. Li L, Lee EW, Ji H, Zukowska Z. Neuropeptide Y-induced acceleration of postangioplasty occlusion of rat carotid artery. Arterioscler Thromb Vasc Biol 2003; 23: 1204-10.
40. Braam B. Renal endothelial and macula densa NOS: integrated response to changes in extracellular fluid volume. Am J Physiol 1999; 276 (Pt 2): R1551-61.
41. Vallance P, Leone A, Calver, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992; 339: 572-5.
42. Ha TK, Sattar N, Talwar D, Cooney J, Simpson K, O'Reilly DS, Lean ME. Abnormal antioxidant vitamin and carotenoid status in chronic renal failure. QJM 1996; 89: 765-9.
43. Herbst U, Toborek M, Kaiser, Mattson MP, Hennig B. 4-Hydroxynonenal induces dysfunction and apoptosis of cultured endothelial cells. J Cell Physiol 1999; 181: 295-303.
44. Arici M, Walls J. End-stage renal disease, atherosclerosis and cardiovascular mortality: is C-reactive protein the missing link? Kidney Int 2001; 59: 407-14.
45. Wassmann S, Stumpf M, Strehlow, Schmid A, Schieffer B, Böhm M, Nickenig G. Interleukin-6 induces oxidative stress and endothelial dysfunction by overexpression of the angiotensin II type 1 receptor. Circ Res 2004; 94: 534-41.
46. Irish A. Cardiovascular disease, fibrinogen and the acute phase response: associations with lipids and blood pressure in patients with chronic renal disease. Atherosclerosis 1998; 137: 133-9.
47. Bologa RM, Levine DM, Parker TS, Cheigh JS, Serur D, Stenzel KH, Rubin AL. Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am J Kidney Dis 1998; 32: 107-14.
48. deFilippi C, Wasserman S, Rosanio S, Tiblier E, Sperger H, Tocchi M, Christenson R, Uretsky B, Smiley M, Gold J, Muniz H, Badalamenti J, Herzog C, Henrich W. Cardiac troponin T and C-reactive protein for predicting prognosis, coronary atherosclerosis, and cardiomyopathy in patients undergoing long term hemodialysis. JAMA 2003; 290: 353-9.
49. Ohtake T, Koboyashi S, Moriya H, Negishi K, Okamoto K,. Maesato K, Saito S. High prevalence of occult coronary artery stenosis in patients with chronic kidney disease at the initiation of renal replacement therapy: an angiographic examination. J Am Soc Nephrol 2005; 16: 1141-8.
50. Herzog CA, MA JZ, Collins AJ. Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engl J Med 1998; 339: 799-805.
51. Aoki J, Nakajima H, Mori M. Clinical and pathologic characteristics of dilated cardiomyopathy in hemodialysis patients. Kidney Int 2005; 67: 333-41.
52. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998; 317 (7160): 703-13. Erratum in: BMJ 1999; 318 (7175): 29.
53. Hansson L, Lindholm LH, Niskanen L. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captorpil Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611-6.
54. Pohl M, Blumenthal S, Cordonnier DJ, De Alvaro F, DeFerrari G, Eisner G, Esmatjes E, Gilbert RE, Hunsicker LG, de Faria JB, Mangili R, Moore J Jr, Reisin E, Ritz E, Schernthaner G, Spitalewitz S, Tindall H, Rodby RA, Lewis EJ; for the Collaborative Study Group. independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the Irbesartan Diabetic Nephropathy Trial (IDNT): clinical implications and limitations. J Am Soc Nephrol 2005; 16: 3027-37.
55. Messerli FH, Kupfer S, Pepine CJ. J curve in hypertension and coronary artery disease. Am J Cardiol 2005; 95: 160.
56. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992; 3: 669-77.
57. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico. GISSI-3: effects of lisinopril and transdermal glyceryl nitrate single and together on 6-week mortality and ventricular function after acute myocardial dysfunction. Lancet 1994; 343: 1115-22.
58. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative group. ISIS-4: a randomized factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 1995; 345: 669-85.
59. Ambrosioni E, Broghi C, Magnani B. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. N Engl J Med 1995; 332: 80-5.
60. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821-8.
61. Brenner BM, Cooper ME, De Zeeuw D, Keane WF, Mitch WE, Parving H-H, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-9.
62. Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau J-L, Drury PL, Esmatjes E, Hricik D, Parikh CR, Raz I, Vanhille P, Wiegmann TB, Wolfe BM, Locatelli F, Goldhaber SZ, Lewis EJ; for the Collaborative Study Group. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med 2003; 138: 542-9.
63. McKelvie RS, Yusuf S, Pericak D, Avezum A, Burns RJ, Probstfield J, Tsuyuki RT, White M, Rouleau J, Latini R, Maggioni A, Young J, Pogue J. Comparison of candesartan, enalapril and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation 1990; 100: 1056-64.
64. Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, Konstam MA, Riegger G, Klinger GH, Neaton J, Sharma D, Thiyagarajan B. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial. The Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355: 1582-7.
65. Dickstein K, Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high risk patients after acute myocardial infarction: the QPTIMAAL randomised trial. Lancet 2002; 360: 752-60.
66. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM; for the Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction or both. N Engl J Med 2003; 349: 1893-906.
67. Parving HH, Rossing P, Hommel E, Smidt UM. Angiotensin-converting enzyme inhibition in diabetic nephropathy: ten years' experience. Am J Kidney Dis 1995; 26: 99-107.
68. Maschio G, Alberti D, Janin G; The Angiotensin-Converting Enzyme Inhibition in Progressive Renal Insufficiency Study Group. Effect of the angiotensin-converting enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 1996; 334: 939-45.
69. Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan V, Rubis N, Gherardi G, Arnoldi F, Ganeva M, Ene-Iordache B, Gaspari F, Perna A, Bossi A, Trevisan Ro, Dodesini AR, Remuzzi G; for the Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004; 351: 1941-51.
70. Kshirsagar AV, Joy MS, Hogan SL, Falk RJ, Colindres RE. Effect of ACE inhibitors in diabetic and nondiabetic chronic renal disease: a systematic overview of randomized placebo-controlled trials. Am J Kidney Dis 2000; 35: 695-707.
71. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-8.
72. Barnett AH, Bain SC, Bouter P, Kartberg B, Madsbad S, Jervell J, Mustonen J; Diabetics Exposed to Telmisartan and Enalapril Study Group. Angiotensin-receptor blockade versus converting enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004; 351: 1952-61.
73. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I; Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-60.
74. Brophy JM, Joseph L, Rouleau JL. Beta-blockers in congestive heart failure: a Bayesian meta-analysis. Ann Intern Med 2001; 134: 550-60.
75. Cice G, Ferrara L, D'Andrea A. Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. J Am Coll Cardiol 2003; 41: 1438-44.
76. Boaz M, Smetana S, Weinstein T, Matas Z, Gafter U, Iaina A. Secondary prevention with antioxidants of cardiovascular disease in end stage renal disease (SPACE): randomised placebo-controlled trial. Lancet 2000; 356: 1213-8.
77. Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, Ritz E; German Diabetes and Dialysis Study Investigators. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353: 238-48.
78. Drueke TB, Locatelli F, Clyne N, Eckardt KU, Mac Dougall IC, Tsakiris D, Burner HU, Scherhag A; CREATE Investigators. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355: 2071-84.
79. Singh AK, Szech L, Tang K, Barnhart H, Sapp S, Wolfson M, Reddan D; The CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085-98.
80. Pinkau T, Mann JFE, Ndrepepa G, Mehilli J, Hadamitzky M, Braun S, Kastrati A, Schömig A. Coronary revascularization in patients with renal insufficiency: restenosis rate and cardiovascular outcomes. Am J Kidney Dis 2004; 44: 627-35.
81. Rose BD. Diuretics. Kidney Int 1991; 39: 336-52.
82. Brater DC, Voelker JR. Use of diuretics in patients with renal disease. In: Bennett WM, McCarron DA, eds. Contemporary issues in nephrology. Pharmacotherapy of renal disease and hypertension, vol 17. New York: Churchill Livingstone, 1987.
83. Ellison DH. Diuretic drugs and the treatment of edema: from clinic to bench and back again. Am J Kidney Dis 1994; 23: 623-43.
84. Brater DC. Analysis of the effect of indomethacin on the response to furosemide in man: effect of dose of furosemide. J Pharmacol Exp Ther 1979; 210: 386-390.
85. Brater DC, Day B. Burdette A, Anderson S. Bumetanide and furosemide in heart failure. Kidney Int 1984; 26: 183-9.
86. Butler J, Emerman C, Peacock WF, Mathur VS, Young JB; on behalf of the VMAC Study Investigators. The efficacy and safety of B-type natriuretic peptide (nesiritide) in patients with renal insufficiency and acutely decompensated congestive heart failure. Nephrol Dial Transplant 2004; 19: 391-9.
87. Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 2005; 111: 1487-91.
88. Gheorghiade M, Gattis WA, O'Connor CM, Adams KF, Elkayam U, Barbagelata A, Ghali JK, Benza RL, McGrew FA, Klapholz M, Ouyang J, Orlandi C; Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure (ACTIV in CHF) Investigators. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA 2004; 291: 1963-71.